Floatz logo

Bexarotene

Breast Atypical Lobular Hyperplasia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Breast Atypical Lobular Hyperplasia cohort.

Asset / SponsorPhaseRating
Ruxolitinib
Julie Nangia
Phase 2B
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 2CCC
4-hydroxytamoxifen
Mayo Clinic
Phase 2CCC
EXEMESTANE
Dana-Farber Cancer Institute
Phase 2CCC
som230
NYU Langone Health
Phase 1CC
Pasireotide
NYU Langone Health
Phase 1CC

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
primary cutaneous anaplastic large cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →